Coronavirus Notebook: EU Opinion On Moderna’s mRNA-1273 Expected This Week, UK Boosts Vaccine Rollout As Lockdown Imposed
UK biotech firm Emergex has signed a deal with Brazil’s Biocruz for the development of a T-cell based vaccine, and the Philippines regulator has issued a warning after reports that members of the country’s presidential guard received an unauthorized vaccine produced by China’s Sinopharm.
You may also be interested in...
AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford.
Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.